URN | urn:agi-cas:105355-27-9 |
---|---|
Total Entities | 0 |
Connectivity | 2934 |
Name | pioglitazone |
Molecular Weight | 392.898000 |
XLogP | 2.341000 |
Pathway | Anti-psoriatic drugs influence PPARG signaling |
---|
MedScan ID | 1043036 |
---|
Alias | pioglitazona |
---|---|
105355-27-9 | |
Actos | |
Pioglitazone hydrochloride | |
U 72107A | |
111025-46-8 | |
(+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-Thiazolidinedione | |
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine-2,4-dione | |
HSDB 7322 | |
U-72107 | |
[3H]pioglitazone | |
pioglitazone | |
5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-Thiazolidinedione (+/-)-monohydrochloride | |
(+/-)-5-[p-[2-[(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione | |
U72107 | |
(+/-) 5-[p-[2-[(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione | |
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | |
AD 4833 | |
Pioglitazone HCl | |
pioglitazonum | |
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione | |
112529-15-4 | |
(+/-)-5-(p-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione monohydrochloride |
CAS ID | 105355-27-9 |
---|---|
112529-15-4 | |
127676-30-6 | |
111025-46-8 | |
198077-89-3 |
Reaxys ID | 11338157 |
---|---|
27504417 | |
3579575 | |
3595485 |
ChEBI ID | 8228 |
---|
PharmaPendium ID | Pioglitazone Hydrochloride |
---|
HMDB ID | HMDB15264 |
---|
KEGG ID | C07675 |
---|
InChIKey | HYAFETHFCAUJAY-UHFFFAOYSA-N |
---|---|
GHUUBYQTCDQWRA-UHFFFAOYSA-N |
Molecular Formula | C19H20N2O3S |
---|---|
C19H21ClN2O3S |
PubChem SID | 135017830 |
---|---|
135035596 |
PubChem CID | 60560 |
---|---|
4829 |
XLogP-AA | 3.8 |
---|
IUPAC Name | 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-quinone |
---|---|
5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-quinone;hydrochloride |
Rotatable Bond Count | 7 |
---|